CSF2 and cutaneous mastocytosis: Subsequently, we performed the CASVAC-0401 randomized, adjuvant Phase II study in CM patients stages IIB, IIC, and III, comparing the CSF-470 vaccine (hereafter VACCIMEL) plus BCG and GM-CSF versus medium dose IFNα2b.